Key facts
- This page summarizes Simon C. Lowry's Form 4 filing for Emergent BioSolutions Inc. (EBS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Mar 2025, 16:17.
Simon C. Lowry - 06 Mar 2025 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)
- Reporting relationship
- SVP, R&D, CMO
- Issuer ticker
- EBS
- Reported as of
- 06 Mar 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Mar 2025, 16:17:54 UTC
- Prior SEC filing
- 17 Dec 2024
- Next SEC filing
- 16 Dec 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard S. Lindahl, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Simon C. Lowry filed Form 4 for Emergent BioSolutions Inc. (EBS) on 10 Mar 2025.
Change
- Previous filing in this sequence was filed on 17 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EBS
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +62,500
- Change %
- +212%
- Price
- $0.000000
- Shares after
- 91,982
- Date
- 06 Mar 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EBS
transaction
Derivative
Employee Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +62,500
- Change %
- +154%
- Price
- $0.000000
- Shares after
- 102,999
- Date
- 06 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 62,500
- Exercise price
- $5.80
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
Footnote F2
Vests in three equal installments beginning on the day prior to the anniversary date of the grant.